Australis Capital Inc. (AUSAF)
OTCMKTS
· Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
May 19, 2025, 4:00 PM EDT
Australis Capital Revenue
In the fiscal year ending March 31, 2022, Australis Capital had annual revenue of 9.47M CAD with 1,221.13% growth. Australis Capital had revenue of 3.10M in the quarter ending March 31, 2022, with 575.81% growth.
Revenue
9.47M CAD
Revenue Growth
+1,221.13%
P/S Ratio
0.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
254.00 USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| BioStem Technologies | 332.45M |
Australis Capital News
- 7 days ago - CSE Bulletin: Delist - Australis Capital Inc. (AUSA) - Newsfile Corp
- 2 years ago - Audacious Management Change - Accesswire
- 2 years ago - Audacious Completes Final New Jersey License Application Step - Accesswire
- 2 years ago - Audacious Provides Investors' Corporate Update - Accesswire
- 2 years ago - Audacious Completes First New York State Cannabis Harvest - Accesswire
- 2 years ago - Audacious Provides Corporate Update - Accesswire
- 3 years ago - Audacious NJ Receives Millville, New Jersey Municipal Resolution of Support Approval for Cannabis Facility - Accesswire
- 3 years ago - Audacious Reports Unaudited Fiscal 2022 Results - Accesswire